

To the shareholders in Medistim ASA**NOTICE OF ORDINARY GENERAL MEETING**

Medistim ASA will hold its ordinary general meeting Wednesday the 25th of April 2018 at 10.00. The meeting will be held at the company headquarter in Økernveien 94 in Oslo.

The agenda for the meeting is as follows:

1. Approval of the notice, registration of shareholders or persons represented by proxy.
2. Appointment of person to chair the meeting, to sign the protocol, to co-sign the protocol and protocol secretary.
3. Approval of annual report for 2017.
4. Approval of the profit and loss and balance sheet for 2017.
5. Approval of the distribution of the profit for the year of TNOK 38,420. The Board of Director's suggests a dividend of NOK 2.00 per share, total TNOK 36,322 corrected for own shares, and that the remaining TNOK 2,098 is distributed to other equity.
6. The Board of Director's declaration on salary and other remuneration to the management. The Board of Director's declaration is included in the holding company annual report for 2017 at page 63.
7. Approval of fee to the auditor for 2017. Fee to the auditor was in total TNOK 459 where TNOK 402 was for the audit and TNOK 57 was for other services.
8. Election of board members. Three of the board members are on election. This is Deputy Chairman Bjørn M. Wiggen, Board Member Tove Raanes and Board Member Lars Rønn. The Nomination Committee suggests that Bjørn M. Wiggen is re-elected as Deputy Chairman for a new term of 2 years to the ordinary General Meeting in 2020. The Nomination Committee suggests further that Lars Rønn and Tove Raanes is re-elected as Board Members for a term of 2 years to the ordinary General Meeting in 2020. All candidates are willing to take a new term. Bjørn M. Wiggen represents the second largest shareholder in Medistim ASA.
9. Fees to the Board. The Nomination Committee proposes to the General Assembly that the Chairman receives a fee for 2017 of NOK 375,000. Furthermore, the Nomination Committee proposes that each of the board members for 2017 will receive a fee of NOK 210,000 for each member. Total fees to the Board according to the Nomination Committee's proposal are NOK 1,215,000.
10. The leader of the Nomination Committee, Johan Skjølberg, is on election, but he is not willing to take a new term. It is suggested to the General Assembly that Bjørn Henrik Rasmussen is elected as leader for the Nomination Committee for one year until the ordinary General Meeting in 2019. It is further suggested that Kristin Eriksen is elected as member of the Nomination Committee for a 2 year term until the ordinary General Meeting in 2020. Kristin Eriksen represents Medistims second largest shareholder.
11. It is suggested to the General Meeting that the leader of the Nomination Committee is compensated with NOK 20,000 and that the members are compensated with NOK 15,000. Total purposed fee to the Nomination Committee is TNOK 50,000.
12. Approval of the Board of Director's suggestion to the general meeting to renew the Board of Director's authorization to increase share capital.
 - A. The Board of Director's is authorized to increase share capital up to NOK 458,433,25 by issuing up to 1,833,733 new shares at par value of NOK 0.25. The share price and other terms when issuing new shares are set by the board of directors. The board of directors can increase the share capital once or in several different occasions.
 - B. In case of a change in par value of the share as a result of a split, fond emission or something similar, the authorization is adjusted accordingly with the number of shares that can be issued. The share price and other terms are adjusted according to generally known principles for such adjustments, but always within the regulations in the Public Limited Companies Act.
 - C. The authorization shall also include capital increase against other assets than cash deposits.
 - D. The shareholders preferential rights to subscribe shares can be set aside by the board according to the Public Limited Companies Act § 10-4.

- E. The authorization shall include a decision including a fusion according to Public Limited Companies Act § 13-5.
- F. The authorization is valid until the next ordinary general meeting.

In line with the company goals the Board of Director's will assess continuously business opportunities, further development and expansion of the business. In order to secure flexibility both time wise and for the financing, the board of director's prefer to have the authorization from the general meeting to have the opportunity to strengthen equity by issuing new shares against cash deposits or other assets, also in relation to a fusion. The authorization can be used to issue shares in relation to convertible loans, acquisition of companies or other commitments in relation to industrial partners or strategic partners.

The purpose of setting aside the preferential rights for existing shareholders to subscribe new shares is to ensure flexibility for the company.

13. Approval of the Board of Director's suggestion to renew the power of attorney to purchase own shares on the following conditions:

- A. The authorization is valid until the next general meeting.
- B. The company can purchase shares at par value up to NOK 458,433.25, which are 1,833,733 shares at today's par value.
- C. The highest price per share shall maximum be NOK 150.00 per share.
- D. The lowest price per share shall minimum be NOK 0.25 per share.
- E. The Board of Director's can freely decide how to purchase the shares as long as the principle for equal treatment is followed.

The purpose of the suggestion is that the company wishes to have available different methods to obtain and secure optimal capital structure.

Notice on participation at the general meeting should be sent to the company one day before the meeting.

Oslo 15th. March 2018

Board of Director's in Medistim ASA

Contact: CEO Kari Eian Krogstad/CFO Thomas Jakobsen
Phone: 23059660
Fax: 23059661
Email: ir@Medistim.com

Attachments:

- 1. Attendance form
- 2. Form of proxy
- 3. Annual report for Medistim ASA for 2017

Attendance form general meeting in Medistim ASA

The undersigned will attend the general meeting in Medistim ASA the 25th of April 2018 starting at 10.00.

Shareholders name

Number of shares

Place

Date

Shareholders signature

Power of attorney

The undersigned, _____, that owns
_____ shares in Medistim ASA hereby give _____
_____ power of attorney to attend and vote for my shares at the general meeting in
Medistim ASA the 25th of April 2018.

Place

Date

Shareholders signature

Shareholders name in block letters

(Companies must attach a copy of company registration of newer date to prove correct signature.)

Medistim ASA
POWER OF ATTORNEY
ORDINARY GENERAL MEETING 25 APRIL 2017

Shareholder who does not return the form "NOTICE OF ATTENDANCE – ORDINARY GENERAL MEETING 25th of APRIL 2018" (Form sent 4th of April)), and therefore wishes to authorise another person to act on his or her behalf at the ordinary general meeting on 25th of April 2018 must complete this power of attorney form and return it to: **Medistim ASA, Økernveien 94, 0479 Oslo or to ir@medistim.com.**

The power of attorney should be received by us **no later than 24th of April 2018 at 16:00 hours (CET)**. The undersigned hereby grants (please tick):

☐

Chairperson of the board Øyvind Brøymer, or the person he appoints, or

☐

Name of attorney (use capital letters)

power of attorney to attend and vote for my/our shares at the ordinary general meeting of Medistim ASA to be held on 25th of April 2018. If the power of attorney form is submitted without stating the name of the attorney, the power of attorney will be deemed to have been given to the chairperson of the board of directors Øyvind Brøymer or the person he appoints. The votes shall be cast in accordance with the instructions below. Please note that **if the alternatives below are not ticked off, this will be deemed to be an instruction to vote "in favour" of the proposals in the notice**, provided, however, that the attorney determines the voting to the extent proposals are put forward in addition to, instead of, or as adjustments to the proposals in the notice.

Item:	In favour	Against	Abstain	attorney's discretion
1. Approval of the notice, registration of shareholders or persons represented by proxy.				
2. Appointment of person to chair the meeting, to sign the protocol, to co-sign the protocol and protocol secretary proposed in the general meeting.				
3. Approval of annual report for 2017.				
4. Approval of profit and loss and balance sheet 2017.				
5. Approval of the distribution of the profit for the year.				
6. The Board of Director's declaration on salary and other remuneration to the management.				
7. Approval of fee to the auditor for 2017.				
8. Election of board members. Three of the board members are on election. This is according to The Nomination Committee's suggestion.				
9. Fees to the Board. This is according to the Nomination Committee's suggestion.				
10. The leader the Nomination Committee is on election. This is according to the Nomination Committee's suggestion.				
11. Compensation to the Nomination Committee. This is according to the Nomination Committee's suggestion.				
12. Approval of the Board of Director's suggestion to the general meeting to renew the Board of Director's authorization to increase share capital.				
13. Approval of the Board of Director's suggestion to renew the power of attorney to purchase own shares				

The shareholder's name and address: _____ (please use capital letters). If the shareholder is a company, please attach documentation in the form of certificate of registration, or separate power of attorney, if applicable, to this power of attorney.

Date

Place

shareholder's signature